Cetera Investment Advisers Acquires Shares of 13,089 BioLife Solutions, Inc. $BLFS

Key Points

• Cetera Investment Advisers invested approximately $299,000 in BioLife Solutions, acquiring 13,089 shares during the first quarter.
• Major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares for $23.80 each, resulting in an 11.48% decrease in their ownership.
• Several analysts have issued mixed ratings for BioLife Solutions, with Zacks Research upgrading it to a "strong-buy" while Wall Street Zen downgraded it to "sell."

Cetera Investment Advisers acquired a new position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 13,089 shares of the medical equipment provider's stock, valued at approximately $299,000.

Other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers grew its holdings in shares of BioLife Solutions by 0.7% in the 1st quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock valued at $1,901,000 after acquiring an additional 566 shares in the last quarter. GAMMA Investing LLC increased its position in shares of BioLife Solutions by 18.6% in the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after acquiring an additional 663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of BioLife Solutions by 5.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,508 shares of the medical equipment provider's stock valued at $532,000 after acquiring an additional 1,047 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions in the fourth quarter valued at about $31,000. Finally, Avantax Advisory Services Inc. increased its position in shares of BioLife Solutions by 16.0% in the first quarter. Avantax Advisory Services Inc. now owns 9,077 shares of the medical equipment provider's stock valued at $207,000 after acquiring an additional 1,250 shares during the last quarter. Institutional investors own 93.24% of the company's stock.

BioLife Solutions Price Performance

BLFS stock traded up $0.83 during midday trading on Friday, reaching $25.91. 652,188 shares of the company were exchanged, compared to its average volume of 557,506. The business has a 50-day moving average price of $22.32 and a two-hundred day moving average price of $23.41. BioLife Solutions, Inc. has a one year low of $19.10 and a one year high of $29.55. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -215.90 and a beta of 1.76.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%.The company had revenue of $25.42 million for the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Insider Activity at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $23.80, for a total value of $23,800,000.00. Following the transaction, the insider owned 7,707,165 shares of the company's stock, valued at approximately $183,430,527. This represents a 11.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 2,008,831 shares of company stock valued at $47,499,658 over the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on BLFS. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price (up previously from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Zacks Research raised shares of BioLife Solutions to a "strong-buy" rating in a research report on Monday, August 11th. Wall Street Zen downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Finally, Stephens started coverage on shares of BioLife Solutions in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $31.29.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.